Mechanisms Tumors : AKT Signaling Dependent and Independent Therapeutic Effect of Imatinib in Gastrointestinal Stromal

@inproceedings{Tarn2006MechanismsT,
  title={Mechanisms Tumors : AKT Signaling Dependent and Independent Therapeutic Effect of Imatinib in Gastrointestinal Stromal},
  author={C. Tarn and Yuliya V. Skorobogatko and T. Taguchi and Burton Eisenberg and Margaret von Mehren and Andrew K. Godwin},
  year={2006}
}
Most gastrointestinal stromal tumors (GISTs) possess a gainof-function mutation in c-KIT . Imatinib mesylate, a smallmolecule inhibitor against several receptor tyrosine kinases, including KIT, platelet-derived growth factor receptor-A, and BCR-ABL, has therapeutic benefit for GISTs both via KIT and via unknown mechanisms. Clinical evidence suggests that a potential therapeutic benefit of imatinib might result from decreased glucose uptake as measured by positron emission tomography using 18… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Similar Papers

Loading similar papers…